Disease Description
“Tourette syndrome is a rare disorder that causes people to make unusual movements or sounds, called “tics.” Common examples of tics include blinking and throat clearing. People with the disorder have little or no control over their tics. Many people with Tourette syndrome have mild symptoms, but some have more severe ones. Most people with Tourette syndrome start showing signs of the disorder before they are 11 years old. In about half of children with Tourette syndrome, the tics go away by the time they turn 18. Tics that continue into adulthood gradually improve over time in many people. But in some people, the tics return later in life.” - Uptodate.com
Prevalence
“In a meta-analysis of 13 studies that specifically assessed TS in children, the prevalence of TS was 7.7 per 1000 children (95% CI 3.9-1.51) [18]. The prevalence was higher in boys compared with girls (10.6 versus 2.5 per 1000).” - Uptodate.com
Current Treatment Options
“Children and adults with Tourette syndrome don’t need medical treatment unless their tics are severe. A person with Tourette syndrome might need treatment if he or she is having problems:
●Talking with other people
●Attending school or working at a job
●Doing everyday things such as bathing, dressing, and eating Treatments include:
●Medicines – Certain medicines used to treat different mental health conditions can lower the number of tics a person has.
●Botulinum toxin (brand name: Botox) – This is a medicine that is given by injection. It works by blocking or calming the nerve signals that make the muscles jerk or twitch.
●Habit reversal training – This treatment involves working with a therapist who teaches people with Tourette syndrome to recognize when they are about to have a tic. Then, the people train themselves to do a different movement that makes it hard to do the tic. This treatment is not available everywhere.” -uptodate.com
Evidence for and Proposed Mechanism for Cannabinoids Therapeutics
"Anecdotal reports have suggested beneficial effects of marijuana (Cannabis sativa) in TS. Sandyk and Awerbuch (2) reported that three TSpatients experienced a significant amelioration of symptoms when using marijuana. These 15- to 39- year-old male patients had noted an improvement of tic severity, urge to tic, self-mutilatory behaviour, attention span, hypersexuality and a generalized relaxation when they smoked half to two marijuana cigarettes per day. Hemming and Yellowlees (3) described a single case of a 36- year-old man who had reported that he had been symptom free for more than 1 year while he was taking one 'cone' of marijuana per night.
Retrospective chart review. Our results provide more evidence that marijuana improves tics and behavioural disorders in TS. It can be speculated that cannabinoids might act through specific receptors, and that the cannabinoid system might play a major role in TS pathology." -Emrich HM, et al. Treatment of Tourette’s Syndrome with Δ9-Tetrahydrocannabinol (THC): A Randomized Crossover Trial. Pharmacopsychiatry 2002; 35: 57-61
In Germany, a study conducted at the Medical School Hannover stated:
"Previous studies provide evidence that marijuana (Cannabis sativa) and Δ9-tetrahydrocannabinol (Δ9-THC), the major psychoactive ingredient of marijuana, respectively, are effective in the treatment of tics and behavioral problems in Tourette syndrome (TS). It, therefore, has been speculated that the central cannabinoid receptor system might be involved in TS pathology. However, in healthy marijuana users there is an ongoing debate as to whether the use of cannabis causes acute and/or long-term cognitive deficits. In this randomized double-blind placebo-controlled study, we investigated the effect of a treatment with up to 10 mg Δ9-THC over a 6-week period on neuropsychological performance in 24 patients suffering from TS. During medication and immediately as well as 5-6 weeks after withdrawal of Δ9-THC treatment, no detrimental effect was seen on learning curve, interference, recall and recognition of word lists, immediate visual memory span, and divided attention. Measuring immediate verbal memory span, we even found a trend towards a significant improvement during and after treatment. Results from this study corroborate previous data suggesting that in patients suffering from TS, treatment with Δ9-THC causes neither acute nor long-term cognitive deficits. Larger and longer-duration controlled studies are recommended to provide more information on the adverse effect profile of THC in patients suffering from TS."
Recent GBXI News:
May 11, 2023, GBX International Group, Inc., (OTC: GBXI)
GBX International Group, Inc. (OTC:GBXI) Confirms 2023 Strong Revenue Growth Guidance Projections by Combining Each Acquired Operating Company Product Release, Expects Strong Growth Sector by Sector Through its Multiple Product Releases into North American and International Markets
April 21, 2023, GBX International Group, Inc., (OTC: GBXI)
HARVARD Award Winning Entrepreneur, Mr. Raymond C. Dabney Acquires Majority Shareholder Control of GBX International Group, Inc. (OTC: GBXI) Makes More History Bringing CSi-EDP Partner American States University (ASU) as the First Acquisition for its Aggressive Growth Plans
The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.
Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.
We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.
Click here to review the Report:
Case No. 2:17-CV-02271-KJM-JDP
Inspire, Dream, Change
YOUR DIGITAL ERA Personal & Business Access Learning HUB
I hope everyone is doing well. Raymond, Francis Cormier wrote a very detailed, informative summery over a month ago. I do not believe his 4 ever...I hope everyone is doing well. Raymond, Francis Cormier wrote a very detailed, informative summery over a month ago. I do not believe his 4 ever important questions have been answered.
(1) Who's working on updating documentation? What's the % complete?
(2) Who owns and/or controls the CBIS Intellectual Property?
(3) is there another entity out there using the same name as Cannabis Science?
(4) WHERE IS BRINGING CBIS BACK PUBLIC AGAIN ON YOUR LIST OF PRIORITIES?
Can you please elaborate on these for us.
Show more
Hi Raymond,
Per the 3rd party Cancer Drug Valuation(s) Full Report linked from this website:
On November 8, 2023; Capizate, Inc. (a 3rd party entity)...Hi Raymond,
Per the 3rd party Cancer Drug Valuation(s) Full Report linked from this website:
On November 8, 2023; Capizate, Inc. (a 3rd party entity) reported a "Situation Analysis of GBXi" that it performed at GBXI's request; based upon 25 documents provided by GBXI; mostly pertaining to Cannabis Science, Inc. This report included listing: (a) Strengths, (b) Areas for Improvement, (c) CBIS Cancer Drug Valuation(s) [1 specifically], (d) as well as several additional items that supported it giving GBXI a Capitize Score = 623 out of a possible 1000. Getting the potential CBIS Drug Valuation(s) for just 1 drug @ 25Mil-29Mil is/was impressive; however the "Areas for Improvement" are significant:
Areas for improvement
---------------------
1. The business documents, agreements, term sheets, engagements are all dated in 2017-2018 and need to be updated.
2. Ownership and control of the intellectual property needs to be defined and confirmed.
3. A similar entity has active registration with California Secretary of State. The Company has a different address than on the Company website and also had a Statement of Info due to the California Secretary of State on 05/10/2023. Registered with the California Secretary of State as a Non-Profit Nonprofit Corporation - CA - Mutual Benefit. This will need to be defined.
Can you please let us know about the progress that has been made toward resolving these issues?? Even if you could reveal an estimated % complete for each line item that would be nice to see.
The report from November 8, 2023 says: "Your current phase in our process is phase three (Situation Analysis), four (Due Diligence Score), and five (Business Finance Documents – Specifically the analysis) the potential valuation" - out of a 7 phase process; (6) Capital Markets and (7) Post Capitalization. Even if you choose not to continue to use Capitize, Inc. any longer; these "Areas of Improvement" listed MUST BE addressed in order to bring CBIS back Trading again.
Thank you in advance of your response and Best Regards,
...Francis G. Cormier III
Show more
Cannabis Science CEO, Presents …
The FINAL “CBIS GIFT Shares” Issuances!
DECEMBER 1, 2022, Cheers! & HAPPY HOLIDAYS !!!
ALL GIFT Shares 1, 2, & 3 being ISSUED !!!
LAST Steps:
Please confirm Yours NOW !!!
1. CONFIRM Correct Total Share Amount(s)
2. CONFIRM Correct Name(s) on CERTIFICATE
3. CONFIRM Correct Mailing Address
ASU/CSi-EDP-ECO-System
At it's FINEST !!!
WHICH ONE ARE YOU ??
Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???
We can make this HAPPEN way FASTER Working as a TEAM !!!
WHAT Matters is how much you CARE about KILLING CANCERS ...
This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.
2023 Audit considerations NASDAQ.
Cannabis Science Inc.
Share Structure 2023
Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.
Common Stock:
Authorized:
5,000,000,000
Issued:
2,521,095,296
Class A Common Stock
Authorized:
100,000,000
Issued:
0
Class B Common Stock
Authorized:
1,500,000,000
Issued:
0
Preferred Stock
Authorized:
1,000,000
Issued:
1,000,000
Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.
You already know our Extensive LIST of GROUNDBREAKING Products.
1-Million STRONG TV Coverage, HARVARD Award Success.
TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE
*** APPLY for FREE in CONFIDENCE and Success.
Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.
EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!
"We Own everything we speak about Owning,... Show more 7 days ago
Now that I'm past that NASTY Sickness phase we can... Show more 7 days ago